Summary：**Sai Life Sciences Reveals Q4FY26 Earnings, Sparking Hope Among Stakeholders****Introduction** Sai

**Sai Life Sciences Reveals Q4FY26 Earnings, Sparking Hope Among Stakeholders**

**Introduction**
Sai Life Sciences unveiled its quarterly results for Q4FY26 on Thursday, posting a modest rebound in revenue that lifted investor sentiment after a turbulent fiscal year. The Hyderabad‑based contract research and manufacturing organization (CRO) reported a 4.2% year‑over‑year increase in turnover, driven by stronger demand for its integrated drug‑development services. Analysts noted that the figures, while not spectacular, signal a turning point as the company steadies its cost base and refocuses on high‑margin projects.

**Key Developments**
The earnings release highlighted several concrete milestones. First, Sai Life Sciences secured three new long‑term agreements with multinational pharmaceutical firms, collectively worth approximately INR 1.2 billion. Second, the firm’s EBITDA margin expanded to 18.5%, up from 16.9% in the prior quarter, reflecting successful cost‑optimization initiatives across its manufacturing units. Third, capex was trimmed by 12% as the management postponed non‑essential facility upgrades, preserving cash flow for debt reduction. Stakeholders responded positively, pushing the stock up 3.8% in intraday trading.

**Industry Analysis**
India’s CRO sector has been navigating a mixed environment: global pharma outsourcing remains robust, yet pricing pressures and regulatory scrutiny have intensified. Sai Life Sciences’ performance mirrors a broader trend where mid‑size players leverage niche therapeutic expertise—particularly in oncology and biologics—to differentiate themselves from larger rivals. The company’s recent investments in automation and data analytics have begun to